Amendment No. 2 to the Research Collaboration and License AgreementResearch Collaboration and License Agreement • March 11th, 2016 • Five Prime Therapeutics Inc • Pharmaceutical preparations • New York
This Amendment No. 2 to the Research Collaboration and License Agreement (this “Amendment”), effective as of July 27, 2015 (the “Amendment Effective Date”), is made by and between UCB Pharma S.A., a Belgium corporation (“UCB”), and Five Prime Therapeutics, Inc., a Delaware corporation (“FivePrime”).
ContractLicense and Collaboration Agreement • March 11th, 2016 • Five Prime Therapeutics Inc • Pharmaceutical preparations • New York
*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
Amendment No. 1 to the Research Collaboration and License AgreementResearch Collaboration and License Agreement • March 11th, 2016 • Five Prime Therapeutics Inc • Pharmaceutical preparations
This Amendment No. 1 to the Research Collaboration and License Agreement (this “Amendment”), effective January 21, 2016 (the “Amendment Effective Date”), is made and entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation (“FivePrime”), and Bristol-Myers Squibb Company, a Delaware corporation (“BMS”).
Respiratory Diseases Research Collaboration and License AgreementRespiratory Diseases Research Collaboration and License Agreement • March 11th, 2016 • Five Prime Therapeutics Inc • Pharmaceutical preparations • Delaware
This Amendment No. 3 to the Respiratory Diseases Research Collaboration and License Agreement, effective as of January 26, 2016 (this “Amendment No. 3”), is made by and between Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 ONN, England (“GSK”), and Five Prime Therapeutics, Inc., a Delaware corporation having a place of business at Two Corporate Drive, South San Francisco, CA 94080, USA (“FivePrime”).
Executive Transition and Severance Benefits AgreementExecutive Transition and Severance Benefits Agreement • March 11th, 2016 • Five Prime Therapeutics Inc • Pharmaceutical preparations • California
Certain capitalized terms used in this Termination Date Release are defined in the Executive Transition and Severance Benefits Agreement (the “Agreement”) which I have executed and of which this Termination Date Release is a part.
